Zoetis has announced the launch of Apoquel (oclacitinib maleate), a new treatment for pruritus associated with canine allergic dermatitis and the clinical manifestations of atopic dermatitis. Zoetis has announced the launch of Apoquel (oclacitinib maleate), a new treatment for pruritus associated with canine allergic dermatitis and the clinical manifestations of atopic dermatitis. 

Uniquely, the new treatment inhibits the JAK enzyme, a protein that is integral to the signalling pathway of cytokines that are pro-inflammatory or have a role in allergic and itch response.

According to the company, pruritus affects about one in six dogs whose owners seek veterinary help, and about half of all itchy dogs will have an underlying allergic skin condition for which the new product would be indicated.

Zoetis says that because Apoquel targets the specific pathways of pruritus (itch) and inflammation, it is less likely to cause unwanted side effects than glucocorticoids and demonstrates anti-pruritic efficacy within four hours.

Pascal Prélaud, a dermatology specialist from Paris, who took part in the clinical development programme of Apoquel, said: "When a dog develops an itch related to an allergy, it can be life-disrupting for the dog and the entire family. I've learned firsthand the fundamental difference this treatment can make to a dog and its owners in stopping the itch, but without many of the side-effects that are common with steroids.

Zoetis reports that in clinical trials, Apoquel demonstrated a good safety profile and efficacy for the treatment of pruritus and resulted in improved skin lesions in dogs diagnosed with a number of allergic skin diseases as well as atopic dermatitis and treated either short or long term. The decrease in itch scores was observed by pet owners within 24 hours of administration, and pruritus continued to decrease compared to baseline until the end of the study.  Skin lesions scores assessed by veterinarians were significantly improved after one week and continued to improve long term during the studies (four months). 

 

Apoquel is a POM. Apoquel tablets, dosed at 0.4 to 0.6 mg/kg, are administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy if medium- to long-term treatment is required, such as in dogs with seasonal skin allergy and atopic dermatitis. 

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.